©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Role of lipid-lowering agents in the management of diabetic retinopathy
Estelle Ioannidou, Vasilis-Spyridon Tseriotis, Konstantinos Tziomalos, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, Greece
Author contributions: Ioannidou E and Tseriotis VS drafted the editorial; Tziomalos K critically revised the draft.
Conflict-of-interest statement: All authors declare no conflict of interest related to this publication.
Correspondence to: Konstantinos Tziomalos, MD, PhD, Assistant Professor of Internal Medicine, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi street, 54636 Thessaloniki, Greece. ktziomalos@yahoo.com
Telephone: +30-2310-994621 Fax: +30-2310-994773
Received: August 13, 2016
Peer-review started: August 16, 2016
First decision: September 2, 2016
Revised: September 17, 2016
Accepted: November 16, 2016
Article in press: November 17, 2016
Published online: January 15, 2017
Processing time: 145 Days and 14.3 Hours
Peer-review started: August 16, 2016
First decision: September 2, 2016
Revised: September 17, 2016
Accepted: November 16, 2016
Article in press: November 17, 2016
Published online: January 15, 2017
Processing time: 145 Days and 14.3 Hours
Core Tip
Core tip: Even though it is unclear whether dyslipidemia is implicated in the pathogenesis of diabetic retinopathy, both preclinical data and two large randomized controlled studies showed that treatment with fenofibrate delays the progression of diabetic retinopathy. In contrast, statins do not appear to play a role in the management of this complication despite the promising findings of animal studies.